Skip to main content

Hypopara Newsroom

If you want to be in the know about what’s going on in the world of HypoPARA, you’ve come to the right place. Be sure to check back regularly to get the latest news updates.

More information on SUP supply and recall status

We have been granted a Listening Session with the FDA to let them know what its really like to live with HypoPara and why advances in research are needed to find better treatments.

We are incredibly excited to share that Calcilytix, a Bridgebio Company, announced early results from an ongoing Phase 2b proof-of-concept, open-label study of encaleret for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1).

Check out the Pathway Trial and see if you are eligible. Both short-term symptoms and long-term complications of HypoPara are addressed with TransCon PTH.

The Rare-Cap program will establish a networked system for the development, dissemination and curation of protocols to help standardize the process of diagnosis and care for patients with rare diseases.

Entera Bio announced the publication of the results of its previously completed Phase 2a study of EB612 (oral PTH) in the Journal of Bone and Mineral Research.

EveryLife Foundation releases study of estimated economic cost of 379 rare diseases.

Potential short‐term supply interruption for some patients receiving NATPARA 75‐mcg or NATPARA 100‐mcg through the Special Use Program (SUP).

Free genetic testing for AD-H1 now available for patients with non-surgical HypoPara.

Agency must show the same urgency for these Americans that it shows for treatment of COVID-19

Takeda shares the latest updates on supply interruptions of Natpara parathyroid hormone

Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. The company is initially applying its technology to develop an oral formulation of parathyroid hormone, Oral PTH (1-34), for treatment of hypoparathyroidism and osteoporosis.

Click for more information. Let your voice be heard!

For a limited time the presentations can be viewed here on the website.

AZP-3601 is currently in development for the treatment of hypoparathyroidism

This information is provided for educational purposes only. It should not be used for diagnostic or treatment purposes. If you wish to obtain more information about this disorder, please contact your personal physician.